CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net income (loss)	$ (54)	$ (17)	$ (983)
Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:
Depreciation and amortization	171	167	154
Amortization of right-of-use assets	29	24	21
Goodwill impairment	0	0	938
Gain on divestiture of a business	0	(73)	0
Share-based compensation expense	46	40	46
Benefit for deferred income taxes	(22)	(32)	(64)
Amortization of debt issuance costs	6	6	5
Other	18	4	(9)
Changes in operating assets and liabilities, net of acquisitions
Accounts receivable, net	15	(68)	13
Inventories, net	(65)	106	(58)
Other assets and liabilities	(59)	(15)	(52)
Accounts payable and accrued expenses	17	(89)	92
Net cash provided by (used for) operating activities	102	53	103
Cash flows from investing activities:
Investments in property, equipment, and software	(60)	(58)	(39)
Payments related to equity investments and business acquisitions, net of cash acquired	(81)	(54)	(26)
Proceeds from divestiture of a business, net	0	103	0
Proceeds from sale of property and equipment	1	4	0
Net cash provided by (used for) investing activities	(140)	(5)	(65)
Cash flows from financing activities:
Proceeds from revolving line of credit	0	190	0
Repayment of revolving line of credit	0	(190)	0
Proceeds from issuance of debt	0	0	1,220
Principal payments of debt	(30)	(122)	(43)
Debt issuance and amendment costs	0	(5)	(24)
Dividend paid to Former Parent	0	0	(1,174)
Proceeds from share-based awards	8	12	6
Tax payments related to share-based awards	(15)	(2)	(1)
Net transfers from Former Parent	0	0	165
Proceeds from issuance of Series A preferred stock	0	250	0
Series A preferred stock issuance costs	0	(6)	0
Series A preferred stock dividend	0	(6)	0
Distributions to non-controlling shareholders	(2)	0	0
Deferred payments related to equity investments and business acquisitions	(13)	(17)	(9)
Payments related to the buy-out of non-controlling interests in subsidiaries of Covetrus	(14)	0	(74)
Net cash provided by (used for) financing activities	(66)	104	66
Effect of exchange rate changes on cash and cash equivalents	(3)	8	3
Net change in cash and cash equivalents	(107)	160	107
Cash and cash equivalents, beginning of period	290	130	23
Cash and cash equivalents, end of period	183	290	130
Supplemental disclosures of cash payments:
Interest	22	40	47
Income taxes	27	24	18
Amounts included in the measurement of operating lease liabilities	27	27	25
Supplemental disclosures of noncash investing and financing activities:
Conversion of Series A preferred stock	0	245	0
Right-of-use assets obtained in exchange for new operating lease liabilities	51	56	104
Right-of-use assets obtained in exchange for new financing lease liabilities	2	0	1
Common stock issued in business acquisition	4	0	0
Deconsolidation of a subsidiary	$ 0	$ 15	$ 0